Though the document offered no details on what the terms of the settlement might be, Bansal wrote that one possible middle ground could be Amgen receiving the right to launch a biosimilar in 2025.Bansal wrote that Alexion was trading between $110 and $120 per share before the lawsuit, and expected the stock to jump back to that range in response to the settlement news.